Beta Bionics, Inc. (BBNX)
| Market Cap | 635.90M +1.6% |
| Revenue (ttm) | 110.24M +57.9% |
| Net Income | -66.44M |
| EPS | -1.51 |
| Shares Out | 44.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 252,809 |
| Open | 14.37 |
| Previous Close | 14.39 |
| Day's Range | 14.12 - 14.60 |
| 52-Week Range | 8.80 - 32.71 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 19.18 (+34.41%) |
| Earnings Date | Jul 28, 2026 |
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which co... [Read more]
Financial Performance
In 2025, Beta Bionics's revenue was $100.25 million, an increase of 53.94% compared to the previous year's $65.12 million. Losses were -$73.20 million, 33.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for BBNX stock is "Buy." The 12-month stock price target is $19.18, which is an increase of 34.41% from the latest price.
News
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
San Diego, California--(Newsfile Corp. - June 9, 2026) - Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The inve...
Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors...
Beta Bionics, Inc. (BBNX) Investigation: Johnson Fistel Investigates Investor Losses Following Slower New Patient Start Growth
SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws.
Beta Bionics management to meet with Piper Sandler
Meeting to be held on June 9-11 hosted by Piper Sandler..
Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws
Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws
Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel
SAN DIEGO--(BUSINESS WIRE)---- $bbnx #BBNX--Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The i...
Beta Bionics Investors Who Suffered Losses May Be Eligible for Recovery-Learn More Today, Contact Johnson Fistel
San Diego, California--(Newsfile Corp. - June 2, 2026) - Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securitie...
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
IRVINE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-ti...
Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders
SAN DIEGO--(BUSINESS WIRE)---- $BBNX #BetaBionicsInc--Shareholder Rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and ...
Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The ...
Beta Bionics price target lowered to $17 from $19 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Beta Bionics (BBNX) to $17 from $19 and keeps a Buy rating on the shares.
Beta Bionics price target raised to $13 from $11 at BofA
BofA analyst Travis Steed raised the firm’s price target on Beta Bionics (BBNX) to $13 from $11 and keeps a Neutral rating on the shares. Beta Bionics says FDA feedback…
Beta Bionics Transcript: AGM 2026
The meeting confirmed a quorum, elected two directors, and ratified the audit firm. No questions were raised by stockholders, and final voting results will be filed in a Form 8-K.
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to...
Beta Bionics price target lowered to $11 from $23 at BofA
BofA analyst Travis Steed lowered the firm’s price target on Beta Bionics (BBNX) to $11 from $23 and keeps a Neutral rating on the shares. After having hosted 34 medtech…
Beta Bionics Transcript: Bank of America Global Healthcare Conference 2026
Q1 revenue exceeded expectations due to pharmacy channel growth and field sales expansion. The company is preparing to launch a new patch pump, Mint, by end of 2027, focusing on user experience and manufacturing readiness. Pricing in the pharmacy channel is expected to remain stable due to product differentiation.
Beta Bionics to Present at the Bank of America Securities Health Care Conference
IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management ...
Beta Bionics price target lowered to $20 from $22 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Beta Bionics (BBNX) to $20 from $22 and keeps a Buy rating on the shares. Q1 results were “relatively solid,”…
Beta Bionics price target lowered to $20 from $32 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Beta Bionics (BBNX) to $20 from $32 and keeps an Overweight rating on the shares. The firm notes Beta…
Beta Bionics reports Q1 EPS (49c), consensus (45c)
Reports Q1 revenue $27.6M, consensus $26.97M.
Beta Bionics Earnings Call Transcript: Q1 2026
Q1 2026 saw 57% revenue growth to $27.6M, with gross margin expanding to 59.5% and strong pharmacy channel traction. Full-year guidance was raised for revenue, gross margin, and pharmacy mix, while cash reserves remain robust and R&D investments accelerate.
Beta Bionics Earnings release: Q1 2026
Beta Bionics released its Q1 2026 earnings on April 21, 2026, summarizing the period's financial results.
Beta Bionics Slides: Q1 2026
Beta Bionics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.
Beta Bionics Quarterly report: Q1 2026
Beta Bionics has published its Q1 2026 quarterly earnings report on April 21, 2026.
Beta Bionics sees FY26 revenue $131M-$136M, consensus $132.58M
Sees FY26 gross margin of 57.5% to 59.5%, previously 55.5% to 57.5%. Sees 37% to 39% of new patient starts reimbursed through the PBP channel, previously 36% to 38%. Published…